Details

Autor(en) / Beteiligte

• DeMill, David L., BA
• Zaugg, Brian E., MD
• Pettey, Jeff H., MD
• Jensen, Jason D., BS
• Jardine, Griffin J., MD
• Wong, Gilbert, MD
• Olson, Randall J., MD

Titel

Objective comparison of 4 nonlongitudinal ultrasound modalities regarding efficiency and chatter

Ist Teil von

• Journal of cataract and refractive surgery, 2012-06, Vol.38 (6), p.1065-1071

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose To compare efficiency and chatter of Infiniti Ozil with and without Intelligent Phacoemulsification (IP) and the Signature Ellips with and without FX. Setting John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA. Design Experimental study. Methods Brunescent 2.0 mm human lens cubes were created by an instrument devised for this study. Cubes were tested (10 per test) for time of particle removal (efficiency) and for the number of times the lens particle bounced off the tip (chatter) at 300 mm Hg and 550 mm Hg, 50% and 100% power, and 50% and 100% amplitudes (amplitude for Ozil only). Results Of the ultrasound settings, efficiency varied from a mean of 3.3 seconds ± 1.4 (SD) to 50.4 ± 11.7 seconds and chatter from 0.0 to 52.0 ± 16.7 bounces per run. The Ozil-IP was generally more efficient than the Ozil and the Ellips FX more efficient than the Ellips. At optimized values, the Ozil-IP and Ellips-FX were similar. In general, efficiency and chatter were better at 550 mm Hg and at 50% power. The amplitude effect was complex. Efficiency closely correlated with chatter (Pearson r2 = .31, P <.0001). Conclusions Objective comparison of phacoemulsification efficiency and chatter found that optimized Ozil-IP and Ellips-FX were similar in both parameters and in general, both performed better than preceding technology. The study parameters can significantly affect efficiency and chatter, which strongly correlate with each other. Financial Disclosure Dr. Olson has been a consultant to Abbott Medical Optics, Inc., Becton, Dickinson and Co., and Allergan, Inc., and has received grant support from Abbott Medical Optics, Inc., and Allergan, Inc. No author has a financial or proprietary interest in any material or method mentioned.